Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain most—but not all—of their weight loss, according to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
News Release • May 13, 2026